Correvio Pharma Corp (NASDAQ:CORV) saw a large decrease in short interest during the month of October. As of October 31st, there was short interest totalling 491,500 shares, a decrease of 20.2% from the September 30th total of 616,100 shares. Based on an average trading volume of 143,500 shares, the short-interest ratio is currently 3.4 days. Currently, 1.9% of the shares of the stock are sold short.
CORV stock traded down $0.01 during mid-day trading on Thursday, reaching $2.19. The company’s stock had a trading volume of 211,300 shares, compared to its average volume of 156,086. The company’s 50 day moving average is $1.98 and its two-hundred day moving average is $2.13. The stock has a market cap of $121.25 million, a PE ratio of -2.46 and a beta of 0.49. The company has a current ratio of 1.68, a quick ratio of 1.45 and a debt-to-equity ratio of 7.21. Correvio Pharma has a fifty-two week low of $1.43 and a fifty-two week high of $4.44.
Correvio Pharma (NASDAQ:CORV) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.21) by ($0.05). The firm had revenue of $7.39 million for the quarter, compared to analyst estimates of $7.64 million. Correvio Pharma had a negative return on equity of 575.20% and a negative net margin of 107.91%. On average, analysts forecast that Correvio Pharma will post -0.72 earnings per share for the current fiscal year.
A number of analysts have commented on the stock. Cantor Fitzgerald assumed coverage on shares of Correvio Pharma in a report on Tuesday, September 3rd. They issued an “overweight” rating and a $6.00 price objective for the company. HC Wainwright reiterated a “buy” rating and issued a $7.00 price objective on shares of Correvio Pharma in a report on Thursday, August 15th. Finally, ValuEngine upgraded shares of Correvio Pharma from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $6.75.
Correvio Pharma Company Profile
Correvio Pharma Corp. operates as a pharmaceutical company, which engages in the provision of development and commercialization of medical products. It operates through the Europe and Rest of the World geographical segments. The firm focuses on cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease.
Featured Story: Net Margin
Receive News & Ratings for Correvio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Correvio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.